Mark Lotter is the founder of Nuance Biotech. Nuance Biotech has raised $181M in total funding. Backed by Matrix Partners, C-Bridge Capital.
Mark Lotter is the founder and CEO of Nuance Biotech, a company he established in January 2015 to build a platform for innovation in China. Nuance Biotech aims to bring innovative compounds to the Chinese market, focusing on oncology and immunology. The company has successfully raised three rounds of funding from investors like Matrix Partners and C-Bridge Capital. Prior to Nuance Biotech, Lotter co-founded NovaMed Pharmaceuticals in 2005, which was acquired by SciClone Pharmaceuticals in 2011.
Full founder directory · Investor directory · Company funding database · Fundraising library